Form 20-F AMBEV S.A. For: Dec 31
Tweet
Share
E-mailhttp://archive.fast-edgar.com/20260303/AN22D22CZ22YBTZ222282ZODKPBK3Z224282
Filed on: March 3, 2026
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
- Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand
- MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
